A PCN theranostic platform comprises a doxorubicin (DXR)-loaded liposomal core and an acid-sensitive polymer shell that is functionalized with Herceptin and GdIII-based MRI contrast agents. In vitro testing reveals a 14-fold increase in DXR-based cytotoxicity versus a non-targeted analogue and an 120-fold improvement in cellular GdIII-uptake in comparison with clinically approved DOTA-GdIII, leading to significant T1 MRI contrast enhancement.

中文翻译：

---

pH 响应性治疗诊断聚合物笼式纳米盒：通过 Her2 靶向增强细胞毒性和 T1MRI 对比

PCN 治疗诊断平台包括负载阿霉素 (DXR) 的脂质体核心和酸敏感聚合物外壳，该外壳用赫赛汀和基于 GdIII 的 MRI 造影剂功能化。体外测试显示，与非靶向类似物相比，基于 DXR 的细胞毒性增加了 14 倍，与临床批准的 DOTA-GdIII 相比，细胞 GdIII 摄取增加了 120 倍，从而显着增强了 T1 MRI 对比度。